Table 1 Treatment doses and delivery routes.
From: TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy
Treatment | Initial dose and delivery site | Subsequent dose and delivery site |
|---|---|---|
Flagellin | 10 μg i.t. or i.p. | 2 μg (8×) i.t. or i.p. |
CBLB502 High Dose | 10 μg i.t. or i.p. | 2 μg (8×) i.t. or i.p. |
CBLB502 Low Dose | 1 μg i.t. or i.p. | 0.2 μg (8×) i.t. or i.p. |
anti-CTLA-4 (9D9) | 200 μg i.p. | 100 μg i.p. (3×) |
anti-PD-1 (RPM1-14) | 200 μg i.p. | 100 μg i.p. (3×) |
